Cargando…

Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies

PURPOSE: We determined the safety, pharmacokinetics, pharmacodynamics and recommended phase II dose of the base excision repair blocker methoxyamine combined with fludarabine. MATERIALS AND METHODS: This was a phase I study with intravenous fludarabine (25 mg/m(2), days 1–5), and methoxyamine (15 mg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caimi, Paolo F., Cooper, Brenda W., William, Basem M., Dowlati, Afshin, Barr, Paul M., Fu, Pingfu, Pink, John, Xu, Yan, Lazarus, Hillard M., de Lima, Marcos, Gerson, Stanton L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668101/ https://www.ncbi.nlm.nih.gov/pubmed/29108368 http://dx.doi.org/10.18632/oncotarget.20094

Ejemplares similares

Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair
por: Bulgar, A D, et al.
Publicado: (2012)

Outcomes of allogeneic hematopoietic stem cell transplantation for lymphomas: a single-institution experience
por: Massoud, Mira Romany, et al.
Publicado: (2016)

Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed–Platinum–Radiation in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer: Results of a Phase I Trial
por: Biswas, Tithi, et al.
Publicado: (2022)

[(18)F]-Fludarabine for Hematological Malignancies
por: Barré, Louisa, et al.
Publicado: (2019)

Synthesis of Fluorescent Dansyl Derivatives of Methoxyamine and Diphenylhydrazine as Free Radical Precursors
por: Patrascu, Bianca, et al.
Publicado: (2020)

Prospective Study of Single vs. Two Unit Umbilical Cord Blood Transplantation Following Reduced Intensity Conditioning in Adults with Hematologic Malignancies
por: Kindwall-Keller, Tamila L., et al.
Publicado: (2011)

IDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells
por: Maleki Vareki, Saman, et al.
Publicado: (2015)

Methoxyamine Enhances 5-Fluorouracil-Induced Radiosensitization in Colon Cancer Cell Line HT29
por: Khoei, Samideh, et al.
Publicado: (2017)

Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas
por: Coyne, Geraldine O'Sullivan, et al.
Publicado: (2020)

Fibrosing Alveolitis in Hematologic Malignancy Patients Undergoing Hematopoietic Cell Transplantation
por: Salman, Huda, et al.
Publicado: (2010)

Impact of age, antiretroviral therapy, and cancer on epigenetic aging in people living with HIV
por: Qing, Yulan, et al.
Publicado: (2023)

Socioeconomic Factors and Survival of Multiple Myeloma Patients
por: Chamoun, Kamal, et al.
Publicado: (2021)

Phase I Trial of Lithium and Tretinoin for Treatment of Relapsed and Refractory Non-promyelocytic Acute Myeloid Leukemia
por: Ueda, Masumi, et al.
Publicado: (2020)

Inhibition of Nucleotide Excision Repair by Fludarabine in Normal Lymphocytes in vitro, Measured by the Alkaline Single Cell Gel Electrophoresis (Comet) Assay
por: Yamauchi, Takahiro, et al.
Publicado: (2002)

Clinical Comparison of Non-Myeloablative Conditioning with Anti-Thymocyte Globulin and Fludarabine for Patients with Hematologic Malignancies
por: Li, Qingshan, et al.
Publicado: (2015)

A detailed smoking history and determination of MYC status predict response to checkpoint inhibitors in advanced non-small cell lung cancer
por: Chiu, Michelle, et al.
Publicado: (2020)

RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR
por: Sakre, Nneha, et al.
Publicado: (2016)

Reduced-toxicity myeloablative conditioning consisting of 8-Gy total body irradiation, cyclophosphamide and fludarabine for pediatric hematological malignancies
por: Hirabayashi, Koichi, et al.
Publicado: (2014)

A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT
por: Tran, Misha C., et al.
Publicado: (2022)

Neurological illness following treatment with fludarabine.
por: Johnson, P. W., et al.
Publicado: (1994)

Busulfan and Fludarabine Conditioning Regimen Given at Hematological Nadir of Cytoreduction Fludarabine, Cytarabine, and Idarubicin Chemotherapy in Patients With Refractory Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation: A Single Arm Pilot Consort Study
por: Tang, Wei, et al.
Publicado: (2015)

Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
por: Saraceni, Francesco, et al.
Publicado: (2017)

Treosulfan–fludarabine–thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies
por: Kalwak, Krzysztof, et al.
Publicado: (2020)

Fludarabine phosphate for the treatment of low grade lymphoid malignancy.
por: Whelan, J. S., et al.
Publicado: (1991)

PIAS3 expression in squamous cell lung cancer is low and predicts overall survival
por: Abbas, Rime, et al.
Publicado: (2015)

Allogeneic Stem Cell Transplantation for Patients with Advanced Hematological Malignancies: Comparison of Fludarabine-based Reduced Intensity Conditioning versus Myeloablative Conditioning
por: Kim, Inho, et al.
Publicado: (2007)

Pharmacogenomic Approach to Identify Drug Sensitivity in Small-Cell Lung Cancer
por: Wildey, Gary, et al.
Publicado: (2014)

Phase I study of intra-osseous co-transplantation of a single-unit cord blood and mesenchymal stromal cells with reduced intensity conditioning regimens
por: Wang, Jiasheng, et al.
Publicado: (2023)

Telomerase Contributes to Fludarabine Resistance in Primary Human Leukemic Lymphocytes
por: Shawi, May, et al.
Publicado: (2013)

Fludarabine in the treatment of chronic lymphocytic leukemia: a review
por: Ricci, Francesca, et al.
Publicado: (2009)

Low-grade lymphoma: Beyond fludarabine-single therapy
por: Park, Eunkyung
Publicado: (2011)

Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia
por: Janssens, Ann, et al.
Publicado: (2009)

Fludarabine-induced bradycardia in a patient with refractory leukemia
por: Chung-Lo, Woei, et al.
Publicado: (2010)

Base excision repair of 8-oxoG in dinucleosomes
por: Menoni, Hervé, et al.
Publicado: (2012)

Novel Non-Invasive Radiomic Signature on CT Scans Predicts Response to Platinum-Based Chemotherapy and Is Prognostic of Overall Survival in Small Cell Lung Cancer
por: Jain, Prantesh, et al.
Publicado: (2021)

A randomized controlled trial of structured palliative care versus standard supportive care for patients enrolled in phase 1 clinical trials
por: Treasure, Michelle, et al.
Publicado: (2021)

Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells
por: Pepper, C, et al.
Publicado: (2007)

Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation
por: Kamijo, Kimimori, et al.
Publicado: (2023)

T-cell large granular lymphocytic leukemia: treatment experience with fludarabine
por: Costa, Renata Oliveira, et al.
Publicado: (2012)

MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia
por: Ferracin, Manuela, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_m8cg1kq2immo27hffboehs6rbi